Your browser doesn't support javascript.
loading
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Privé, Bastiaan M; Slootbeek, Peter H J; Laarhuis, Babette I; Naga, Samhita Pamidimarri; van der Doelen, Maarten J; van Kalmthout, Ludwike W M; de Keizer, Bart; Ezziddin, Samer; Kratochwil, Clemens; Morgenstern, Alfred; Bruchertseifer, Frank; Ligtenberg, Marjolijn J L; Witjes, J Alfred; van Oort, Inge M; Gotthardt, Martin; Heskamp, Sandra; Janssen, Marcel J R; Gerritsen, Winald R; Nagarajah, James; Mehra, Niven.
Affiliation
  • Privé BM; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Slootbeek PHJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Laarhuis BI; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Naga SP; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van der Doelen MJ; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Kalmthout LWM; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • de Keizer B; Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Ezziddin S; Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Kratochwil C; Department of Nuclear Medicine, Saarland University, Homburg, Germany.
  • Morgenstern A; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Bruchertseifer F; Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre (JRC), Karlsruhe, Germany.
  • Ligtenberg MJL; Directorate for Nuclear Safety and Security, European Commission, Joint Research Centre (JRC), Karlsruhe, Germany.
  • Witjes JA; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Oort IM; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Gotthardt M; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Heskamp S; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Janssen MJR; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Gerritsen WR; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Nagarajah J; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Prostate Cancer Prostatic Dis ; 25(1): 71-78, 2022 03.
Article in En | MEDLINE | ID: mdl-34253846
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant Type of study: Observational_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Prostate Cancer Prostatic Dis Journal subject: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Year: 2022 Document type: Article Affiliation country: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant Type of study: Observational_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Prostate Cancer Prostatic Dis Journal subject: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Year: 2022 Document type: Article Affiliation country: Netherlands